Table 1.
Patient characteristics at the study investigation. Data are described as mean ± SD or absolute numbers (%)
|
Patients with obesity n = 78 |
Normal to overweight individuals n = 18 |
|
|---|---|---|
| Age (years) | 47 ± 10 | 42 ± 15 |
| Sex (male/female) | 26/52 | 3/15 |
| Body weight (kg) | 121 ± 22 | 71 ± 11 |
| BMI (kg/m2) | 41 ± 5.8 | 25 ± 3.5 |
| Total cholesterol (mmol/L) | 3.9 ± 0.95 | 4.4 ± 0.87 |
| Triglycerides (mmol/L) | 1.3 ± 0.59 | 0.93 ± 0.47 |
| LDL (mmol/L) | 2.4 ± 0.82 | 2.5 ± 0.77 |
| HDL (mmol(L) | 0.96 ± 0.20 | 1.5 ± 0.36 |
| hs-CRP (mg/L) | 5.7 ± 6.0 | 2.5 ± 3.8 |
| ALT (U/L) | 39 ± 21 | 22 ± 15 |
| NAFLD liver fat score | 1.1 ± 2.0 | − 1.7 ± 1.1 |
| CYP3A4 genotype (likely phenotype) | ||
| *1/*1 (normal metabolizer) | 74 (95%) | 16 (89%) |
| *1/*22 (intermediate metabolizer) | 4 (5%) | 2 (11%) |
| CYP3A5 genotype (likely phenotype) | ||
| *1/*3 (intermediate metabolizer) | 7 (9%) | 3 (17%) |
| *3/*3 (poor metabolizer) | 71 (91%) | 15 (83%) |
ALT alanine aminotransferase, BMI body mass index, CYP cytochrome P450, HDL high-density lipoproteins, hs-CRP high-sensitivity C-reactive protein, LDL low-density lipoproteins, NAFLD non-alcoholic fatty liver disease